Hao Xiong

5.8k total citations · 2 hit papers
132 papers, 4.4k citations indexed

About

Hao Xiong is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Hao Xiong has authored 132 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Oncology, 36 papers in Molecular Biology and 31 papers in Genetics. Recurrent topics in Hao Xiong's work include PARP inhibition in cancer therapy (25 papers), Chronic Lymphocytic Leukemia Research (15 papers) and Glioma Diagnosis and Treatment (14 papers). Hao Xiong is often cited by papers focused on PARP inhibition in cancer therapy (25 papers), Chronic Lymphocytic Leukemia Research (15 papers) and Glioma Diagnosis and Treatment (14 papers). Hao Xiong collaborates with scholars based in United States, China and Australia. Hao Xiong's co-authors include Rod Humerickhouse, Andrew Krivoshik, Todd Busman, Sari H. Enschede, Yue Cui, Cunyi Fan, Kim L. R. Brouwer, Yi‐Lin Chiu, Evelyn McKeegan and Andrew W. Roberts and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Hao Xiong

131 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

2010 663 citations Wyndham H. Wilson, Owen A. O’Connor et al. The Lancet Oncology profile →
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

2011 632 citations Hao Xiong, Yue Cui et al. profile →

Peers

Countries citing papers authored by Hao Xiong

Since Specialization

Citations

This map shows the geographic impact of Hao Xiong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hao Xiong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hao Xiong more than expected).

Fields of papers citing papers by Hao Xiong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hao Xiong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hao Xiong. The network helps show where Hao Xiong may publish in the future.

Co-authorship network of co-authors of Hao Xiong

This figure shows the co-authorship network connecting the top 25 collaborators of Hao Xiong. A scholar is included among the top collaborators of Hao Xiong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hao Xiong. Hao Xiong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development and Validation of a Deep-Learning Model to Predict Total Hip Replacement on Radiographs 2023 ·Journal of Bone and Joint Surgery ·(unknown), Hao Xiong, (unknown), (unknown), (unknown), Wei Wang, Hongjiang Ruan, Ziyang Sun, Cunyi Fan	3
2	Multifunctional Extracellular Matrix Hydrogel with Self-Healing Properties and Promoting Angiogenesis as an Immunoregulation Platform for Diabetic Wound Healing 2023 ·Gels ·Zhenghua Sun, Hao Xiong, (unknown), (unknown), Yi Xu, Shiyang Yu, Hui Wang, Wanjun Liu, Liang Yang, (unknown), Cunyi Fan	13
3	Development of an In Vitro Drug Release Method to Enable In Vitro–In Vivo Correlation of Potassium Chloride Extended-Release Tablets 2022 ·Molecular Pharmaceutics ·Yihong Qiu, (unknown), (unknown), (unknown), Hao Xiong	4
4	Clinical Effect of Iodine-125 Seed Implantation in Patients with Primary Liver Cancer and Its Effect on Th1/Th2 Cells in Peripheral Blood 2021 ·Journal of Oncology ·(unknown), Fan Zhu, Bin Wang, Yu Zhou, Hao Xiong, Tao Fan, (unknown)	8
5	A Phase 1 and Biodistribution Study of ABT-806i, an ¹¹¹In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806 2021 ·Journal of Nuclear Medicine ·Hui Gan, Matthew Burge, Benjamin Solomon, Sze Ting Lee, Kyle D. Holen, Yumin Zhang, Marika Ciprotti, (unknown), Wijith Munasinghe, (unknown), Peter Ansell, Gerard B. Fox, Hao Xiong, Edward B. Reilly, Rod Humerickhouse, Andrew M. Scott	15
6	Extracellular vesicles from hydroxycamptothecin primed umbilical cord stem cells enhance anti-adhesion potential for treatment of tendon injury 2020 ·Stem Cell Research & Therapy ·Juehong Li, Zhixiao Yao, Hao Xiong, Haomin Cui, Xu Wang, Wei Zheng, Yun Qian, Cunyi Fan	32
7	A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours 2018 ·British Journal of Cancer ·Jordan Berlin, Ramesh K. Ramanathan, John H. Strickler, Deepa S. Subramaniam, John L. Marshall, Yoon‐Koo Kang, (unknown), Matthew W. Dudley, Jiewei Zeng, Caroline Nickner, Hao Xiong, Philip Komarnitsky, Stacie Peacock Shepherd, Herbert I. Hurwitz, Heinz‐Josef Lenz	27
8	Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer 2017 ·Cancer Science ·Shin Nishio, Munetaka Takekuma, Satoshi Takeuchi, (unknown), Naotake Tsuda, (unknown), Nobutaka Takahashi, Masakazu Abé, Aki Tanaka, (unknown), Tadahiro Shoji, Hao Xiong, Silpa Nuthalapati, (unknown), (unknown), (unknown), Philip Komarnitsky, Yasuyuki Hirashima, Kimio Ushijima	21
9	A Phase 1 and Biodistribution Study of Abt-806I, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-Egfr Antibody Abt-806 2017 ·Internal Medicine Journal ·Hui Gan, Matthew Burge, Benjamin Solomon, (unknown), Kyle D. Holen, (unknown), Marika Ciprotti, (unknown), Thomas Merdan, Wijith Munasinghe, (unknown), Peter Ansell, Gerard B. Fox, Hao Xiong, (unknown), Rod Humerickhouse, Andrew M. Scott	2
10	Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer 2017 ·Cancer Chemotherapy and Pharmacology ·Rajendar K. Mittapalli, Silpa Nuthalapati, Stacie Peacock Shepherd, Hao Xiong	3
11	Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer 2016 ·Clinical Cancer Research ·Suresh S. Ramalingam, Normand Blais, Julien Mazières, Martin Reck, C. Michael Jones, Erzsébet Juhász, László Urbán, С. В. Орлов, Fabrice Barlési, Ebenezer A. Kio, (unknown), Qin Qin, Jiang Qian, Caroline Nickner, (unknown), Hao Xiong, Peter Ansell, Mark D. McKee, Vincent L. Giranda, В. А. Горбунова	65
12	Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma 2016 ·Neuro-Oncology ·David A. Reardon, Andrew B. Lassman, Martin J. van den Bent, Priya Kumthekar, Ryan Merrell, Andrew M. Scott, Lisa Fichtel, Erik P. Sulman, Erica Gomez, (unknown), Ho‐Jin Lee, Wijith Munasinghe, Hao Xiong, (unknown), Lisa Roberts-Rapp, Peter Ansell, Kyle D. Holen, Hui Gan	86
13	Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study 2015 ·Journal of Neuro-Oncology ·Minesh P. Mehta, Ding Wang, Fen Wang, Lawrence Kleinberg, (unknown), H. Ian Robins, Aruna Turaka, (unknown), (unknown), Hao Xiong, Nael M. Mostafa, Martin Dunbar, Zhu Ming, Jane Qian, Kyle D. Holen, Vincent L. Giranda, Walter J. Curran	75
14	469P Highly selective c-Met inhibitor tepotinib plus gefitinib is active in Asian patients with c-Met+ NSCLC 2015 ·Annals of Oncology ·Ross A. Soo, D.-W. Kim, (unknown), K. Park, Uz Stammberger, Hao Xiong, Christian Ihling, Yi‐Long Wu	3
15	Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia 2014 ·Cancer Chemotherapy and Pharmacology ·(unknown), Jianning Yang, Peter Noertersheuser, Sven Mensing, Rod Humerickhouse, Walid M. Awni, Hao Xiong	118
16	Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity breakdown → 2010 ·The Lancet Oncology ·Wyndham H. Wilson, Owen A. O’Connor, Myron S. Czuczman, Ann S. LaCasce, John F. Gerecitano, John P. Leonard, Anil Tulpule, Kieron Dunleavy, Hao Xiong, Yi‐Lin Chiu, Yue Cui, Todd Busman, Steven W. Elmore, Saul H. Rosenberg, Andrew Krivoshik, Sari H. Enschede, Rod Humerickhouse	663
17	P2-251: Phase 1/2 study evaluating the safety and efficacy of ABT-751 in combination with docetaxel vs docetaxel alone in subjects with advanced or metastatic non-small-cell lung cancer 2007 ·Journal of Thoracic Oncology ·Helen Eliopoulos, Nashat Gabrail, A. Coates, Xiangdong Zhou, Hao Xiong, A. Hagey	1
18	Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics 2006 ·Clinical Pharmacology & Therapeutics ·David A. Katz, (unknown), David R. Grimm, Hao Xiong, Rhonda R. Holley-Shanks, Thomas Mueller, Brenda F. Leake, (unknown), Lulu Han, (unknown)	72
19	Pharmacokinetics of 5 (and 6)-Carboxy-2′,7′-Dichlorofluorescein and Its Diacetate Promoiety in the Liver 2003 ·Journal of Pharmacology and Experimental Therapeutics ·Maciej J. Zamek‐Gliszczynski, Hao Xiong, Nita Patel, Ryan Z. Turncliff, Gary M. Pollack, Kim L. R. Brouwer	143
20	Mechanisms of Impaired Biliary Excretion of Acetaminophen Glucuronide after Acute Phenobarbital Treatment or Phenobarbital Pretreatment 2002 ·Drug Metabolism and Disposition ·Hao Xiong, Hiroshi Suzuki, Yuichi Sugiyama, Peter J. Meier, Gary M. Pollack, Kim L. R. Brouwer	71

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact